Skip to main
ALT

Altimmune (ALT) Stock Forecast & Price Target

Altimmune (ALT) Analyst Ratings

Based on 4 analyst ratings
Buy
Strong Buy 50%
Buy 50%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Altimmune is a well-positioned company with several key candidates in late-stage development, including their lead candidate pemvidutide, which has a balanced dual-action approach targeting both glucagon and GLP-1 receptors. Based on recent updates, it appears that the company is progressing smoothly towards initiating their PERFORMA pivotal trial and completing enrollment for their RECLAIM trial, further de-risking their development pipeline. With a strong financial position and potential for significant market opportunity in both MASH and ALD, Altimmune presents a compelling investment opportunity with a positive outlook for their stock.

Bears say

Altimmune is facing significant competition in the anti-NASH and obesity therapeutic markets, which may impact its future market penetration and sales revenue. The company's current financials and projections suggest a need for additional fundraising, which could result in share dilution. The successful development and commercialization of pemvidutide is crucial for Altimmune, and any delays or failures in these processes could negatively impact the company's business and stock price.

Altimmune (ALT) has been analyzed by 4 analysts, with a consensus rating of Buy. 50% of analysts recommend a Strong Buy, 50% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Altimmune and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Altimmune (ALT) Forecast

Analysts have given Altimmune (ALT) a Buy based on their latest research and market trends.

According to 4 analysts, Altimmune (ALT) has a Buy consensus rating as of Aug 24, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $13.50, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $13.50, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Altimmune (ALT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.